Yaral Pharma Inc., the US generics subsidiary of IBSA, a long-standing, multinational pharmaceutical company headquartered in Lugano, Switzerland, launched in Parsippany today with the mission of providing access to high quality, affordable, authorized generics (AG) and complex generic medicines to enhance healthcare outcomes.
Led by a team of industry veterans, Yaral Pharma will begin commercializing the first product from IBSA’s corporate pipeline of authorized generics in January 2023. Yaral Pharma’s current portfolio includes products across a range of therapeutic areas, including pain and endocrinology. It plans to rapidly expand its product line and therapeutic areas of focus through outside opportunities and external partnerships.
IBSA is known for its manufacturing expertise and track record of product quality and supply continuity. The company continues to build a wide-ranging portfolio of products across brands and generics in 10 core therapeutic areas including pain and inflammation and endocrinology and manufactures novel delivery systems including soft gel capsules and patch technology. IBSA is also recognized as one of the largest players worldwide in the area of reproductive medicine and one of the world’s leaders in hyaluronic acid-based products.
“Our parent company IBSA is recognized as a world leader in the development of innovative technologies and products that improve the health and wellness of people,” said Stephen Beckman, CEO, Yaral Pharma. “We look forward to drawing on these strengths and providing our customers with high-quality products, continuity of supply, and exceptional levels of service.”
IBSA was founded in 1945 in Lugano, Switzlerland. Today, its products are available in more than 90 countries on 5 continents, through the company’s 17 subsidiaries located in Europe, China, and the United States. The company employ more than over 2,000 people between headquarters, subsidiaries and production sites.
To access more business news, visit NJB News Now.Related Articles: